Asahi Kasei Bioprocess America, Inc.
Biotechnology ResearchView the employees at
Asahi Kasei Bioprocess America, Inc.-
Samuel Twohig Laboratory Technician at Asahi Kasei Bioprocess America, Inc.
-
Rising Star
Sara Guagliardo Field Applications Specialist at Asahi Kasei Bioprocess-
Greater Chicago Area
-
Rising Star
Tsion Akalu Field Applications at Asahi Kasei Bioprocess America, Inc.-
Greater Philadelphia
-
Rising Star
Bryce Fan Biochemistry Student at University of Rochester-
Greater Boston
-
Rising Star
Bunthunvoath Chea Laboratory Coordinator at Asahi Kasei Bioprocess America, Inc.-
Rising Star
Overview
As a global partner to the biopharmaceutical industry, Asahi Kasei Bioprocess helps biologics manufacturers safely and efficiently produce medicines that patients can trust, by dependably supplying innovative yet exceptionally reliable bioprocess consumables, equipment and scientific support services. Our portfolio is anchored by Planova™ virus removal filters. First released in 1989 as the world's first hollow fiber filter developed specifically for removing viruses from biotherapeutic drug products, Planova™ filters ensure viral safety of biopharmaceutical drug products, thanks to their high quality and consistent performance. Leveraging 30 years of experience, we continue to provide our customers with products, services and expertise to achieve assurance that is beyond expectation. As part of our dedication to solving therapeutic product safety, efficiency and purity challenges, we also manufacture a comprehensive suite of downstream equipment. With technology platforms for virus filtration, chromatography, inline buffer formulation and oligonucleotide synthesis, our bioprocessing systems, columns and automation solutions advance GMP manufacturing of critical drug substances around the world. Our portfolio of market-driven equipment and cutting-edge technology touches unit operations across a wide range of therapeutic modalities, including classical small molecule pharmaceuticals, current-generation antibodies, plasma derivatives and next-generation oligonucleotide therapeutics.
-